EGFR and lung carcinoma: Kaplan-Meier survival curves demonstrated significantly reduced survival for N39-positive patients in each subset grouped by age, stage, EGFR/KRAS/ALK alteration status, and smoking history, with the exception of patients with stage II lung cancer (Fig. 5A), presumably reflecting the reduced sample size.